Kite Pharma Licences Teneobio’s Antibody Platform to Fight Multiple Myeloma
By Ruchi Jhonsa, Ph.D. Today, Kite Pharma, a subsidiary of Gilead Sciences, announced that it has entered into license and collaboration agreement with Teneobio, a clinical-stage biotechnology company gaining exclusive …
Read More